78157-26-3

Basic information

• Product Name: 6-(4-pyridinyl)-3(2H)-pyridazinone(SALTDATA: FREE)
• Synonyms: 6-(4-pyridinyl)-3(2H)-pyridazinone(SALTDATA: FREE);6-(pyridin-4-yl)pyridazin-3(2H)-one;3-pyridin-4-yl-1H-pyridazin-6-one;6-Pyridin-4-yl-2H-pyridazin-3-one;6-(4-pyridinyl)-3(2H)-pyridazinone
• CAS NO: 78157-26-3
• Molecular Formula: C₉H₇N₃O
• Molecular Weight: 173.18
• Mol File: 78157-26-3.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-(4-pyridinyl)-3(2H)-pyridazinone(SALTDATA: FREE)(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(4-pyridinyl)-3(2H)-pyridazinone(SALTDATA: FREE)(78157-26-3)
• EPA Substance Registry System: 6-(4-pyridinyl)-3(2H)-pyridazinone(SALTDATA: FREE)(78157-26-3)

Safety Data

• Hazardous Substances Data: 78157-26-3(Hazardous Substances Data)

Usage

General Description

6-(4-pyridinyl)-3(2H)-pyridazinone, also known as SALTDATA: FREE, is a chemical compound with a molecular formula of C10H8N2O. It is a pyridazinone derivative that has a pyridine ring attached to the carbon atom at the 6th position and a ketone functional group. 6-(4-pyridinyl)-3(2H)-pyridazinone(SALTDATA: FREE) is commonly used in pharmaceutical research and drug development due to its potential biological activities. It has been studied for its antibacterial, antifungal, and antitumor properties. Additionally, it has been investigated for its potential as a central nervous system depressant. SALTDATA: FREE also shows potential as an anti-inflammatory agent, making it a versatile compound with various potential applications in the field of medicine and pharmacology.

Upstream product

• 1122-54-9 methyl (4-pyridyl) ketone 
• 298-12-4 Glyoxilic acid 
• 147849-83-0 4,5-Dihydro-4-hydroxy-6-(4-pyridyl)-3(2H)-pyridazinone 
• 80843-48-7 2,3-dihydro-3-oxo-6-(4-pyridinyl)-4-pyridazinecarboxylic acid 
• 696-54-8 pyridine-4-aldoxime 
• 160427-18-9 2-Hydroxy-4-oxo-4-pyridin-4-yl-butyric acid ethyl ester 
• 158840-84-7 ethyl 3-(4-pyridyl)-4,5-dihydroisoxazole-5-carboxylate 
• 1338225-40-3 C₉H₉NO₄ 
• 1692-15-5 4-pyridylboronic acid 
• 79472-17-6 3-chloro-6-(pyridin-4-yl)pyridazine 

Downstream Products

• 923061-48-7 C₁₆H₁₂ClN₃S 
• 79472-17-6 3-chloro-6-(pyridin-4-yl)pyridazine 

Relevant articles and documents

Towards dual inhibitors of the MET kinase and WNT signaling pathway; Design, synthesis and biological evaluation

Both the kinase MET and the WNT signaling pathway are attractive targets in cancer therapy, and synergistic effects have previously been observed in animal models upon simultaneous inhibition. A strategy towards a designed multiple ligand of MET and WNT signaling is pursued based on the two hetero biaryl systems present in both the MET inhibitor tepotinib and WNT signaling inhibitor TC-E 5001. Initial screening was conducted to find the most suitable ring systems for further optimization, whereas a second screen explored modifications towards pyridazinones and triazolo pyridazines. Up to 54% reduction of WNT signaling activity at 10 μM concentration was achieved, however, only low affinities towards MET were observed. Overall, the thiophene substituted pyridazinone 40 was the best dual MET and WNT signaling inhibitor, with a 17% and 19% reduction of activity, respectively. Although further optimizations are needed to achieve more potent dual inhibitors, the strategy presented herein can be valuable towards the development of a dual inhibitor of MET and WNT signaling.

Structure-activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators

Excitatory amino acid transporter 2 (EAAT2) is the major glutamate transporter and functions to remove glutamate from synapses. A thiopyridazine derivative has been found to increase EAAT2 protein levels in astrocytes. A structure-activity relationship study revealed that several components of the molecule were required for activity, such as the thioether and pyridazine. Modification of the benzylthioether resulted in several derivatives (7-13, 7-15 and 7-17) that enhanced EAAT2 levels by >6-fold at concentrations 50 of 0.5 μM.

PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS

The present invention relates to compounds according to the general formula (I), with the definitions of the substituents X, R1 and R2 given below in the text, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. Formula (I) These compounds are kinase inhibitors, in particular inhibitors of the kinase GSK-15 30 (glycogen synthase kinase-3?).